Cosunter(SZ:300436)2021-10-26 16:00Financial Performance - The company's revenue for Q3 2021 was ¥97,744,325.87, representing a slight increase of 0.19% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥3,434,423.19, a significant decrease of 194.32% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was -¥5,046,217.39, reflecting a decline of 485.01% compared to the previous year[2]. - The company reported a significant increase in capital reserves, which reached ¥657,768,634.69, up 272.83% from the previous year-end due to premium share issuance[6]. - The company reported a narrowing loss in Q3 2021 compared to previous quarters, indicating improved financial performance[13]. - Net profit for the third quarter of 2021 was CNY -19,429,076.04, compared to a net profit of CNY 16,527,419.15 in the same period of 2020, indicating a significant decline[22]. - The net profit attributable to the parent company was -20,531,919.56 CNY, compared to a profit of 15,012,979.21 CNY in the same period last year[23]. - The total comprehensive income attributable to the parent company was -20,531,919.56 CNY, while the previous year's figure was 15,012,979.21 CNY[23]. - The basic and diluted earnings per share were both -0.1404 CNY, compared to 0.1072 CNY in the same period last year[23]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,427,164,685.05, an increase of 41.90% from the end of the previous year[2]. - As of September 30, 2021, total current assets increased to CNY 577,566,370.74 from CNY 257,540,926.76 as of December 31, 2020, representing a growth of approximately 124.5%[19]. - The company's total liabilities decreased to CNY 364,487,735.69 from CNY 423,793,648.69, a reduction of about 13.9%[20]. - The company's long-term equity investments increased to CNY 91,815,873.36 from CNY 69,929,129.03, a growth of approximately 31.3%[19]. - Cash and cash equivalents significantly increased to CNY 446,023,048.57 from CNY 135,989,349.92, representing a growth of about 228.5%[19]. - The total assets of the company reached CNY 1,427,164,685.05, up from CNY 1,005,780,979.42, indicating an increase of approximately 41.9%[20]. - The company's capital reserve increased to CNY 657,768,634.69 from CNY 176,426,940.02, reflecting a substantial growth of about 272.5%[20]. Cash Flow - The company reported a net cash flow from operating activities of -¥8,737,728.68, a decrease of 182.52% year-on-year[6]. - The net cash flow from operating activities was -8,737,728.68 CNY, a decrease from 10,588,502.12 CNY in the previous year[26]. - The cash inflow from financing activities was 613,466,566.26 CNY, compared to 110,020,000.00 CNY in the same period last year[26]. - The net cash flow from financing activities was 429,172,634.54 CNY, significantly higher than 50,316,687.37 CNY in the previous year[27]. - The total cash inflow from operating activities was 322,215,445.59 CNY, compared to 315,395,999.69 CNY in the same period last year[26]. - The company reported a cash outflow from investing activities of 113,401,436.27 CNY, compared to 62,114,906.96 CNY in the previous year[26]. Research and Development - Research and development expenses for the first nine months of 2021 were ¥44,620,348.61, an increase of 47.93% compared to the same period in 2020[6]. - Research and development expenses rose to CNY 44,620,348.61 in Q3 2021, compared to CNY 30,162,730.70 in Q3 2020, marking an increase of about 48.0%[22]. - The company has ongoing clinical trials for other innovative drugs, including GST-HG141, GST-HG131, GST-HG151, and GST-HG121, with progress reported as smooth[14]. - The company is actively preparing for the II phase clinical trial of GST-HG141, following successful patient enrollment in the Ib phase trial[14]. - The company completed the I phase clinical trial for the new c-Met targeted drug GST-HG161, with good overall safety and tolerance observed[13]. Share Issuance and Financing - The company issued 18,777,000 shares to specific investors, increasing total share capital from 140,000,000 to 158,777,000 shares[14]. - The total amount raised from the issuance of shares was approximately RMB 514.49 million, with a net amount of RMB 499.58 million after deducting issuance costs[16]. - The company raised ¥429,172,634.54 from financing activities, a substantial increase of 752.94% year-on-year due to issuing shares to specific investors[6]. - The company plans to use RMB 50 million and RMB 30 million to increase capital in its subsidiaries, Fujian Guangshengtang Jintang Pharmaceutical Co., Ltd. and Jiangsu Zhongxing Pharmaceutical Co., Ltd.[16]. Product Development and Market Activity - New products such as Peginterferon and Sildenafil tablets were launched in July 2021, with expected revenue contributions accelerating in the future[13]. - The company won bids for the fifth batch of national drug centralized procurement for Rivaroxaban tablets, which began supply in late September 2021[13]. Audit and Compliance - The company did not undergo an audit for the third quarter report[28].